Table 3 Treatments for patients with acute leukemia and myelodysplastic syndrome
Treatment for AL/MDS | Percent of patients | |
---|---|---|
AL (n=38) | MDS (n=57) | |
HMA (azacitadine or decitabine) | 8 | 28 |
Cytarabine-based | 79 | 19 |
Allo-HSCT | 11 | 5 |
Hyper-CVAD | 8 | 0 |
IMID | 3 | 11 |
FTI/TKI | 3 | 9 |
Other | 3 | 7 |
None | 3 | 18 |